2024
Comparing Cochlear Implant Outcomes in 100 Patients With Sporadic Vestibular Schwannoma Managed With Observation, Radiosurgery, or Microsurgery: A Multi-Institutional Review
Dornhoffer J, Marinelli J, Lohse C, Cottrell J, McMenomey S, Roland J, Thompson N, Brown K, Lucas J, Babu S, Lindquist N, Perkins E, Rahne T, Plontke S, Tan D, Hunter J, Harvey E, Deep N, Cerasiello S, Kircher M, Espahbodi M, Tooker E, Lloyd S, Carlson M. Comparing Cochlear Implant Outcomes in 100 Patients With Sporadic Vestibular Schwannoma Managed With Observation, Radiosurgery, or Microsurgery: A Multi-Institutional Review. Otology & Neurotology 2024, 45: e719-e726. PMID: 39514427, DOI: 10.1097/mao.0000000000004298.Peer-Reviewed Original ResearchConceptsOpen-set speech perceptionCochlear implantationSpeech perceptionSpeech perception test scoresSpeech perception outcomesSpeech perception scoresCochlear implant outcomesPure-tone thresholdsPure-tone averageImplant outcomesSporadic VSVestibular schwannomaIpsilateral CIPerception outcomesVestibular schwannoma managementTreated with observationPerception scoresMulti-institutional reviewSporadic vestibular schwannomaMicrosurgical resectionPatient counselingMultimodal therapyTumor managementRadiosurgeryPatientsProceedings from an international consensus meeting on ablation in urogenital diseases
Iezzi R, Contegiacomo A, De Filippis A, Gunn A, Atwell T, Mcclure T, Jing Z, Posa A, Scrofani A, Maresca A, Madoff D, Goldberg S, Kelekis A, Filippiadis D, Sala E, Ahmed M. Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Into Imaging 2024, 15: 267. PMID: 39514046, PMCID: PMC11549275, DOI: 10.1186/s13244-024-01841-2.Peer-Reviewed Original ResearchInternational Consensus MeetingAblation techniqueIntermediate-risk prostate cancerImage-guided ablation techniquesPreoperative surgical riskManagement of oncological diseasesRenal cell carcinomaConsensus meetingTraditional surgical treatmentGenitourinary tract diseaseFibroid SymptomCell carcinomaProstate cancerSurgical riskAblation therapyImprove patient outcomesTumor managementSurgical treatmentMechanism of actionEffective alternativeTherapeutic alternativeSite of applicationEffective treatmentUrogenital diseasesOncological diseases
2022
Characteristics, Management, and Outcomes of Patients With Osteosarcoma: An Analysis of Outcomes From the National Cancer Database
Ottesen TD, Shultz BN, Munger AM, Sibindi C, Yurter A, Varthi AG, Grauer JN. Characteristics, Management, and Outcomes of Patients With Osteosarcoma: An Analysis of Outcomes From the National Cancer Database. JAAOS Global Research And Reviews 2022, 6: e22.00009. PMID: 35192571, PMCID: PMC8865506, DOI: 10.5435/jaaosglobal-d-22-00009.Peer-Reviewed Original ResearchConceptsLikelihood of deathDistant metastasisKaplan-Meier survival curvesNational Cancer DatabaseOutcomes of patientsPoor prognostic signMultivariate Cox analysisMeier survival curvesAnalysis of outcomesPatient characteristicsCox analysisPrognostic signSurgical excisionMale sexPatient survivalPatient numbersCancer DatabasePatient variablesTumor managementPrimary siteTumor typesSurvival curvesTreatment dataOsteosarcomaPatients
2002
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors
Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors. Cancer 2002, 94: 1593-1611. PMID: 11920518, DOI: 10.1002/cncr.10372.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAnti-EGFR monoclonal antibodiesMonoclonal antibodiesHuman tumorsEnglish-language literature searchEpidermal growth factor receptor (EGFR) positive tumorsMonoclonal antibody therapyReceptor-positive tumorsEGFR monoclonal antibodyDevelopment of malignancyGrowth of tumorsABX-EGFGrowth factor receptorIMC-C225Overall survivalAntibody therapyTraditional cytotoxicsCommon malignancyPoor prognosisClinical trialsEpithelial tumorsVivo effectsTumor managementUnmet needEMD 55900
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply